Short homologous peptides based on C-terminal sequences of fibrinogen β- And γ-chains (haptides) affect cardiovascular function by eNOS inhibition

Journal of Vascular Research

Volumn 47, Issue 6, 2010, Pages 507-518

  Basheer, Maamoun ^a   Schwalb, Herzl ^a   Gilon, Dan ^a   Doviner, Victoria ^a   Sherman, Yoav ^a   Shapira, Oz M ^a   Gorodetsky, Raphael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Endothelial nitric oxide synthase; Fibrinogen; Fibrinolysis; Haptides; Hemodynamic; Isolated heart; Nitric oxide; Rat

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; HAPTIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PEPTIDE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NOS3 PROTEIN, HUMAN; NOS3 PROTEIN, RAT;

ANIMAL CELL; AORTA CONSTRICTION; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CELL ISOLATION; CONTROLLED STUDY; CORONARY ARTERY; DOSE RESPONSE; DRUG MECHANISM; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HOMOGENATE; HUMAN; HUMAN CELL; INTERNAL MAMMARY ARTERY; ISOLATED HEART; MALE; MAMMARY ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING; VASOCONSTRICTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CORONARY BLOOD VESSEL; DRUG EFFECTS; ENZYMOLOGY; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; IN VITRO STUDY; METABOLISM; PERFUSION; PROTEIN TERTIARY STRUCTURE; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FIBRINOGEN; HEMODYNAMICS; HUMANS; MALE; MAMMARY ARTERIES; MYOCYTES, CARDIAC; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDES; PERFUSION; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VASOCONSTRICTION; VENTRICULAR FUNCTION, LEFT; IN VITRO TECHNIQUES;

EID: 77951604923     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313878     Document Type: Article

References (36)

1. Paparella D, Brister SJ, Buchanan MR: Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-1881.
2. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK: Prospective study of fibri-nolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21:611-617. (Pubitemid 32323396)
3. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al: Plasma fibrin-ogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799-1809.
4. Marder VJ, Shulman NR, Carroll WR: High molecular weight derivatives of human fi-brinogen produced by plasmin. I. Physico-chemical and immunological characterization. J Biol Chem 1969; 244:2111-2119.
5. Walker JB, Nesheim ME: The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. Biol Chem 1999; 274: 5201-5212.
6. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al: Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-1235.
7. Baglin T: Disseminated intravascular coagulation: diagnosis and treatment. BMJ 1996; 312:683-687.
8. Gaffney PJ, Brasher M, Lord K, Strachan CJ, Wilkinson AR, Kakkar V V, et al: Fibrin sub-units in venous and arterial thromboembo-lism. Cardiovasc Res 1976; 10:421-426.
9. Michiels JJ, Palareti G, de Moerloose P: Fibrin D-dimer testing for venous and arterial thrombotic disease. Semin Vasc Med 2005; 5: 311-314.
10. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM: C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Ar-terioscler Thromb Vasc Biol 2001; 21:603-610.
11. Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3:1894-1904.
12. Gorodetsky R, Levdansky L, Vexler A, Shimeliovich I, Kassis I, Ben Moshe M, et al: Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. J Control Release 2004; 95:477-488.
13. Gorodetsky R, Vexler A, Shamir M, An J, Levdansky L, Shimeliovich I, et al: New cell attachment peptide sequences from conserved epitopes in the carboxy termini of fi-brinogen. Exp Cell Res 2003; 287:116-129.
14. Gorodetsky R, Vexler A, An J, Mou X, Marx G: Haptotactic and growth stimulatory effects of fibrin(ogen) and thrombin on cultured fibroblasts. J Lab Clin Med 1998; 131: 269-280.
15. Marx G, Ben-Moshe M, Magdassi S, Goro-detsky R: Fibrinogen C-termina l pept idic sequences (Haptides) modulate fibrin polymerization. Thromb Haemost 2004; 91:43-51.
16. Lucas MA, Fretto LJ, McKee PA: The relationship of fibrinogen structure to plasmin-ogen activation and plasmin activity during fibrinolysis. Ann NY Acad Sci 1983; 408: 71-91.
17. Walker JB, Nesheim ME: The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274: 5201-5212.
18. Neely JR, Rovetto MJ: Techniques for perfusing isolated rat hearts. Methods Enzymol 1975; 39:43-60.
19. Khaliulin I, Borman JB, Chevion M, Schwalb H: Cardioprotective and antioxidant effects of apomorphine. Free Radic Res 2003; 37: 721-730.
20. Ren J, Wold LE: Measurement of cardiac me-chanica l f unction in isolated ventricular my-ocytes from rats and mice by computerized video-based imaging. Biol Proced Online 2001; 3:43-53.
21. Wang W, Inoue N, Nakayama T, Ishii M, Kato T: An assay method for nitric oxide syn-thase in crude samples by determining product NADP. Anal Biochem 1995; 227:274-280.
22. Radovits T, Lin LN, Zotkina J, Gero D, Szabo C, Karck M, et al: Poly(ADP-ribose) poly-merase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur J Pharmacol 2007; 564:158-166.
23. Nguyen HG, Korach A, Collura C, Eskenazi BR, Vita JA, Shapira OM: Differential effects of natriuretic peptides on arterial and venous coronary artery bypass conduits. Ann Thorac Surg 2009; 87:748-756.
24. Pober JS, Gimbrone MA, Lapierre LA, Men-drick DL, Fiers W, Rothlein R, Springer TA: Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986; 137:1893-1896.
25. 15 N] nitrate in biological f luids. Anal Biochem 1982; 126: 131-138.
26. Lorenzet R, Sobel JH, Bini A, Witte LD: Low molecular weight fibrinogen degradation products stimulate the release of growth factors from endothelial cells. Thromb Hae-most 1992; 68:357-363.
27. Shimojo N, Jesmin S, Zaedi S, Soma M, Ko-bayashi T, Maeda S, et al: EPA effect on NOS gene expression a nd on NO level in endothe-lin-1-induced hypertrophied cardiomyo-cytes. Exp Biol Med (Maywood) 2006; 231: 913-918.
28. Yevdokimova NY, Veselovska LD, Gogolin-ska GK, Buchanevich OM, Kosyakova GV, Gritsenko PG, et al: Fibrin D-dimer impairs the accumulation and anticoagulant properties of heparan sulphate and stimulates secretion of plasminogen activator inhibitor-1 by rabbit coronary endothelial cells. Acta Biochim Pol 2003; 50: 279-2 89.
29. Davis MR, Ortegon DP, Clouse WD, Kerby JD, DeCaprio JD, Chiou A, et al: Luminal thrombus disrupts nitric oxide-dependent endothelial physiology. J Surg Res 2002; 104: 112-117.
30. Kashyap VS, Reil TD, Moore WS, Hoang TX, Gelabert HA, Byrns RE, et al: Acute arterial thrombosis causes endothelial dysfunction: a new paradigm for thrombolytic therapy. J Vasc Surg 2001; 34: 323-329.
31. Reil TD, Moore WS, Kashyap VS, Nene SS, Gelabert HA, Quinones-Baldrich WJ: The effects of thrombus, thrombectomy and thrombolysis on endothelial function. Eur J Vasc Endovasc Surg 2000; 19: 162-168.
32. Davis MR, Ortegon DP, Kerby JD, Ignarro LJ, Kashyap VS: Endothelial dysfunction after arterial thrombosis is ameliorated by L-arginine in combination with thrombolysis. J Vasc Inter v Radiol 2003; 14 : 233-239.
33. Salerno JC, Harris DE, Irizarry K, Patel B, Morales AJ, Smith SME, Martasek P, Roman LJ, Masters BSS, Jones CL, et al: An autoin-hibitory control element defines calcium-regulated isoforms of nitric oxide synthase. J Biol Chem 1997; 272: 29769-29777.
34. Michel JB, Feron O, Sase K, Prabhakar P, Michel T: Caveolin versus calmodulin. Counterbalancing allosteric modulators of endo-thelial nitric oxide synthase. J Biol Chem 1997; 272:25907-25912.
35. Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, et al: Nitric oxide and cardiac function. Life Sci 2007; 81 : 779-793.
36. Kojda G, Kottenberg K: Regulation of basal myocardial function by NO. Cardiovasc Res 1999; 41: 514-523.